Introduction:
Pharma stock launched an affordable diabetes care treatment targeting Type 2 Diabetes, heart failure, and chronic kidney disease. Backed by USFDA-approved manufacturing, this launch strengthens its healthcare portfolio, offering cost-effective, high-quality solutions addressing rising diabetes cases and related complications.
Share Price movement of Morepen Laboratories:
On March 18, 2025, Morepen Laboratories Limited opened at ₹43.97, reaching a high of ₹47.81, up 10.74% from its previous close of ₹42.84, with a low of ₹43.64. The stock is currently trading at ₹47.44, with a market cap of ₹2,599.49 Crores.
Morepen Laboratories launched treatment for type 2 diabetes:
Morepen Laboratories launched Empamore, an affordable treatment for Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease. Manufactured in USFDA-approved facilities, Empamore offers cost-effective diabetes care, reflecting Morepen’s 40-year pharmaceutical expertise and commitment to accessible, high-quality healthcare solutions.
Empamore includes Empagliflozin tablets and combinations with Metformin, addressing diabetes, cardiovascular, and renal complications. Designed for affordability, it ensures greater access to treatment. With diabetes cases rising, this launch provides timely, patient-centric care without compromising safety and efficacy, meeting global quality standards.
Morepen’s legacy includes installing 12.33 million glucometers and selling 1.65 billion glucose strips. Empamore strengthens their diabetes care leadership, offering innovative packaging and broad healthcare access. Available in 82 countries, Morepen reaffirms its mission to make healthcare affordable globally.
Also Read: Restaurant stock hits 5% upper circuit after clearing ₹205 Cr debt
Stock performance of Morepen Laboratories for Period of 1 week, 6 months and 1 year:
Morepen Laboratories stock declined 4.97% over the past week, followed by a steep 48.9% drop in the last six months. Despite short-term losses, the stock managed to deliver a modest 1.76% return over one year, reflecting slight positive performance in the long term.
Also Read: Hotel stock jumps after signing agreement for 50 room hotel in Bokaro
Shareholding pattern of Morepen Laboratories:
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 35.65 | 35.65 | 38.22 |
| FII | 2.22 | 2.08 | 1.67 |
| DII | 1.64 | 1.69 | 2.14 |
| Retail & others | 60.47 | 60.58 | 57.97 |
About Morepen Laboratories:
Morepen Laboratories Ltd (NSE: MOREPENLAB) is a leading pharmaceutical company specializing in manufacturing APIs, branded formulations, and healthcare devices. With a strong presence in domestic and global markets, it focuses on diabetes care, respiratory products, and wellness solutions, delivering affordable healthcare innovations worldwide.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
